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Recent advances have provided a clearer pic-
ture of the pathways by which the innate im-
mune system senses bacterial and viral pathogens, 
and how this leads to the production of type   
I IFNs. This process is primarily mediated by 
the engagement of specific Toll-like recep-
tors (TLRs) but also by TLR-independent 
pathways. The specific ligands recognized by 
IFN-/–inducing TLRs include dsRNA for 
TLR3 (1), LPS for TLR4 (2), ssRNA for TLR7 
and 8 (3, 4), and unmethylated CpG-DNA for 
TLR9 (5). Ligand binding leads to TLR dimer-
ization and conformational changes in both   
the receptor ectodomains and the cytoplas-
mic TLR–IL-1R (TIR) domains. TIR domains 
bind specific adaptors: TIR domain–contain-
ing  adaptor  inducing  IFN-  (TRIF)  for 
TLR3; TRIF-related adaptor molecule, TRIF,   
TIR domain–containing adaptor protein, and   
MyD88 for TLR4; and MyD88 for TLR7, 8, 
and 9 (6, 7). These adaptors propagate signaling 
by recruiting kinases that mediate activation of 
the transcription factors adaptor protein 1 (AP-1; 
heterodimer of activating transcription factor 
2  and  c-Jun),  NF-B,  IFN  regulatory  factor 
(IRF) 3, and IRF7, which are all required for 
IFN-/ production. Two cytosolic RNA he-
licases, retinoic acid–inducible gene I (RIG-I) 
and melanoma differentiation–associated gene 5 
(MDA5), mediate TLR-independent IFN-/ 
induction by actively replicating RNA viruses 
and  synthetic  RNA  (8).  RIG-I  and  MDA5 
bind through caspase recruitment domains to 
mitochondrial IFN- promoter stimulator 1 
(9),  initiating  signaling  cascades  that  lead  to 
IRF3, IRF7, NF-kB, and AP-1 activation, and 
IFN-/ expression. In addition to viral cyto-
solic RNA, bacterial cytosolic DNA also trig-
gers TLR-independent type I IFN production 
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Myeloid heme oxygenase–1 regulates innate 
immunity and autoimmunity by modulating 
IFN- production
Sotiria Tzima, Panayiotis Victoratos, Ksanthi Kranidioti, Maria Alexiou,  
and George Kollias
Biomedical Sciences Research Center “Alexander Fleming,” Vari 166-72, Greece
Heme oxygenase–1 (HO-1) is a key cytoprotective, antioxidant, and antiinflammatory 
molecule. The pathophysiological functions of HO-1 have been associated with its enzy-
matic activities in heme catabolism. We have examined the immune functions of HO-1 by 
its conditional ablation in myeloid cells (HO-1M-KO mice). We demonstrate that myeloid 
HO-1 is required for the activation of interferon (IFN) regulatory factor (IRF) 3 after Toll-
like receptor 3 or 4 stimulation, or viral infection. HO-1–deficient macrophages show 
reduced expression of IFN- and of primary IRF3 target genes encoding RANTES, IP-10 
and MCP-1. In the presence of polyI:C, myeloid HO-1 knockout mice infected with Listeria 
monocytogenes, a model dependent on IFN- production, showed enhanced bacterial 
clearance and survival, whereas control mice succumbed to infection. Moreover, after 
induction of experimental autoimmune encephalomyelitis, mice with myeloid-specific HO-1 
deficiency developed a higher incidence and an exacerbated, nonremitting clinical  
disease correlating with persistent activation of antigen-presenting cells, enhanced  
infiltration of Th17 cells, and a nonregressing myelin-specific T cell reactivity. Notably, 
these defects were rectified by exogenous administration of IFN-, confirming that HO-1 
functions directly upstream of this critical immune pathway. These results uncover a novel 
direct function for myeloid HO-1 in the regulation of IFN- production, establishing HO-1 
as a critical early mediator of the innate immune response.
© 2009 Tzima et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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(13), that the HO-1 deficiency is partially embryonic lethal. 
HO-1KO mice showed a progressive chronic inflammatory 
disease characterized by enlarged spleens and hepatic inflam-
matory lesions (Fig. 1 C), and died within 6 mo because of 
presumed multiorgan failure. Immunoblot analysis of thio-
glycollate-elicited peritoneal macrophage (TEPM) extracts from 
HO-1KO mice showed complete ablation of HO-1 at the pro-
tein level (Fig. 1 D).
For  myeloid-restricted  ablation  of  HO-1,  we  crossed 
Hmox1FL/FL mice with LysM-Cre knockin mice. The LysM-
Cre transgene mediates excision of loxP-flanked sequences in 
macrophages and granulocytes (22). Immunoblot analysis 
of TEPM extracts from LysMCre/+Hmox1FL/FL and LysMCre/+ 
Hmox1D/FL mice demonstrated efficient ablation of HO-1 at 
the  protein  level  as  compared  with  TEPM  extracts  from 
Hmox1FL/FL or Hmox1+/+ mice (Fig. 1 D). Mice with myeloid-
restricted HO-1 deficiency were born at the expected Men-
delian ratio, were viable and fertile, and did not show apparent 
abnormalities.  Histological  analysis  of  organ  sections  from 
these mice did not demonstrate any gross morphological de-
fects (unpublished data).
HO-1 is not required for NF-B and MAPK activation  
in response to TLR4 and TLR3 stimulation
To investigate innate immune defects in the absence of myeloid 
HO-1, peritoneal macrophages from LysMCre/+Hmox1FL/FL 
(HO-1M-KO) and Hmox1FL/FL (control) mice were stimulated 
in vitro with LPS or polyI:C, and phosphorylation of the 
NF-B and MAPKs was examined. Activation of IKK1, 
IKK2, IB, ERK1/2, JNK2, and p38 occurred to the same 
extent and with similar kinetics in control and HO-1M-KO mac-
rophages in response to LPS (Fig. S1 A) or polyI:C (Fig. S1 B). 
Moreover, no significant differences were observed in the 
production of TNF or IL-6 between control and HO-1M-KO 
macrophages or BM macrophages (BMDMs) from HO-1KO 
mice in response to LPS or polyI:C (Fig. S1, C–E). Collec-
tively, these results suggest that HO-1 is not required for TLR3- 
and  TLR4-mediated  activation  of  the  NF-B  or  AP-1 
pathways in macrophages.
HO-1 deficiency impairs IFN- production induced  
by TLR4 or TLR3 and is required for the induction  
of primary IRF3 target genes in macrophages
TLR3 and TLR4 signals induce gene transcription through 
DNA motifs, designated IFN-stimulated response elements 
(ISREs), found in promoters of genes that bind the IRF 
family of transcription factors (23, 24). These include early 
inflammatory genes, antiviral cytokines, and chemokines (25). 
We therefore examined whether HO-1 is required for the 
induction of these genes in response to dsRNA or LPS.   
After being stimulated with polyI:C, HO-1–deficient mac-
rophages showed significantly attenuated IFN- production 
as  compared  with  control  cells  (Fig.  2  A).  Similarly,  the 
amount of IFN- produced after LPS stimulation of HO-
1–deficient macrophages was severely impaired (Fig. 2 A). 
We also examined whether HO-1 is required for the induction 
through an as yet not fully defined pathway that requires 
IRF3, but not activation of NF-B and mitogen-activated 
protein kinases (MAPKs).
Heme oxygenase–1 (HO-1) is a key cytoprotective, anti-
oxidant, and antiinflammatory molecule. Most of the physio-
logical functions of HO-1 have been associated with its 
enzymatic activity in heme catabolism (10, 11). In humans, 
HO-1 deficiency is associated with susceptibility to oxidative 
stress and an increased proinflammatory state with severe en-
dothelial damage (12). Mice lacking HO-1 develop progres-
sive inflammatory disease (13) and show enhanced sensitivity 
to LPS-induced toxemia (14). The protective properties of 
HO-1 have been studied in a variety of inflammatory models 
(15–20); however, the molecular mechanisms, timing, and 
mode of HO-1 function in disease remain largely unknown.
Earlier studies have shown that HO-1 expression or CO 
administration mediate potent antiinflammatory effects in 
monocytes and/or macrophages (16, 17), probably restrain-
ing these cells from inducing tissue injury and possibly 
modulating their role in the initiation of immune responses. 
However, little is known about the signaling pathways that 
are regulated by HO-1 in macrophages, a cell type central 
to the initiation of immune and autoimmune responses. In 
this study, we sought to examine the function of HO-1 in 
immune responses by conditional ablation of HO-1 gene 
expression,  specifically  in  macrophages.  We  demonstrate 
that HO-1 is not essential for TLR4/MyD88-induced NF-
B and MAPK activation and subsequent proinflammatory 
cytokine  production,  but  is  required  for  TLR4/TLR3/
IRF3-induced production of IFN- and primary IRF3 tar-
get genes in macrophages. In addition, IRF3 activation and 
subsequent  IFN-  production  was  severely  impaired  in 
HO-1 knockout macrophages infected with Sendai virus 
(SeV). In the presence of polyI:C, myeloid HO-1 knock-
out mice infected with Listeria monocytogenes, an infectious 
model with enhanced severity that is dependent on IFN- 
production, showed enhanced bacterial clearance, whereas 
control mice succumbed to infection. Furthermore, myeloid 
HO-1  deficiency  exacerbated  experimental  autoimmune 
encephalomyelitis (EAE) in mice that was associated with 
defective IFN- production and enhanced infiltration of 
activated macrophages and Th17 cells in the central ner-
vous system (CNS).
RESULTS
Ubiquitous and myeloid-specific inactivation of HO-1  
in mice
To investigate the function of HO-1 in immune responses, 
we generated mice with conditional deletion of the Hmox1 
allele (Fig. 1 A). To generate mice with ubiquitous deletion 
of the Hmox1 gene (Hmox1D/D or HO-1KO mice), we crossed 
Hmox1FL/FL  mice  with  transgenic  mice  expressing  Cre  in 
germ cells (21). We confirmed deletion of Hmox1 in the 
germline by Southern blot analysis (Fig. 1 B). Of 622 new-
born pups obtained by intercrossing Hmox1+/D mice, we ob-
tained 25 HmoxD/D mice, indicating, as previously described JEM VOL. 206, May 11, 2009 
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HO-1 interacts with IRF3 and is required for its activation
A common feature of the IFN-, RANTES, and IP-10 genes 
is that multiple transcriptional regulatory elements are required 
for their activation. For example, IFN- gene expression re-
quires the coordinate activation of the transcription factors 
IRF3 (26), NF-B, and activating transcription factor 2/c-Jun 
(27). Various studies have established an essential role for IRF3 
in LPS- and polyI:C-induced IFN-, RANTES, and IP-10 
gene expression (25, 28). We therefore sought to examine 
whether HO-1 deficiency interferes with the activation of 
these transcription factors. To determine NF-B activity in 
the absence of HO-1 in polyI:C-induced gene expression, 
we stimulated TEPMs from control and HO-1M-KO mice with 
polyI:C  for  several  time  points,  and  nuclear  extracts  were   
analyzed for DNA binding activity by EMSA using a probe 
specific for the B site. No significant difference was observed 
in the kinetics of NF-B binding in HO-1–deficient extracts 
as compared with controls (Fig. 2 C), a finding that is in agree-
ment with the results described in Fig. S1 B. We next assayed 
IRF3 DNA binding by EMSA using the IFN- and virus-
  inducible ISREs of the Isg15 gene. Stimulation of control 
macrophages with polyI:C led to the detection of two com-
plexes. The faster migrating complex corresponded to IRF3, 
whereas the slower complexes corresponded to IRF3 associ-
ated with the p300/CBP coactivators (29). In the absence of 
HO-1, IRF3 binding was reduced (Fig. 2 D). IRF3 primarily 
exists in two forms, a monomeric form that shuttles between 
of chemokine genes encoding RANTES, IP-10, MCP-1, 
MIP-1a, and MIP-1b in macrophages. HO-1–deficient and 
control TEPMs were stimulated with LPS for several time 
points and mRNA expression of all five chemokine genes 
was analyzed. Induction of genes encoding RANTES, IP-
10, and MCP-1 was severely impaired in HO-1–deficient 
TEPMs compared with controls (Fig. 2 B). To eliminate the 
possibility that the observed defects are caused by an intrinsic 
defect in the expression of LPS/dsRNA receptors, we also 
analyzed induction of all known LPS/dsRNA receptors in 
response to LPS or polyI:C stimulation. Induction of genes 
encoding TLR4, TLR3, RIG-I, MDA5, and protein kinase 
regulated by RNA (PKR) occurred to the same extent in 
LPS- or polyI:C-treated macrophages from control and 
HO-1M-KO mice (Fig. S2). Finally, we questioned whether 
expression of IFN- and HO-1 in macrophages trigger a 
“positive feedback loop” in which IFN- (or TLR3 and/or 
TLR4 stimulation) up-regulates HO-1 and HO-1 mediates 
IFN- expression. A similar phenomenon has been shown 
to mediate the antiinflammatory effect of IL-10 in macrophages 
in which IL-10 up-regulates HO-1 and HO-1 up-regulates 
IL-10 (17). To address this, we stimulated macrophages with 
LPS, polyI:C, and rIFN-, and we analyzed HO-1 protein 
expression by Western blotting. We found that LPS treat-
ment led to a significant induction of HO-1 protein expres-
sion, whereas polyI:C or rIFN- did not induce HO-1 at all 
time points tested (Fig. S3).
Figure 1.  Generation and characterization of Hmox1 conditional knockout mice. (A) The genomic structures of the mouse Hmox1 gene, the target-
ing vector, and the floxed (FL) and defloxed (D) alleles are shown. Black boxes denote coding sequences. Hmox1FL/FL mice were crossed with the appropriate 
Cre-bearing deleter to obtain mice with ubiquitous or cell-type specific Hmox1 deficiencies. (B) Southern blot analysis of offsprings. Genomic DNA was 
extracted digested with NheI (Nh), electrophoresed, and hybridized with the probe indicated in A. The blotting gave a single 8.8-kb band for the wild-type 
allele, a single 11-kb band for the floxed allele, and a single 12-kb band for the defloxed (D) allele. (C) Spleen (a and b) and hepatic (c and d) sections from 
16-wk-old Hmox+/+ and HmoxD/D mice stained with H&E. Bars, 100 µM. (D) Immunoblot analysis for the expression of HO-1 protein. TEPMs from Hmox+/+ 
(1), Hmox1FL/FL (2), LysMCre/+Hmox1FL/FL (3), LysMCre/+Hmox1D/FL (4), and HmoxD/D (5) mice were stimulated with 50 µM hemin for 24 h, lysed, and blotted with 
anti–HO-1 antibody. The WCEs were simultaneously blotted with anti–-actin antibody. Black lines indicate that intervening lanes have been spliced out.1170 HO-1 MODULATES IRF-3–DEPENDENT TYPE I INTERFERON PRODUCTION | Tzima et al.
reduced in macrophages lacking HO-1 (Fig. S4). To investi-
gate whether HO-1 interacts with IRF3, we performed   
coimmunoprecipitation experiments using whole-cell extracts 
(WCEs) from control and HO-1M-KO macrophages treated 
with hemin to induce endogenous HO-1 protein and/or 
polyI:C. HO-1 immunoblot analysis on cell lysates that were 
immunoprecipitated with an anti-IRF3 antibody revealed that 
HO-1 interacts with IRF3 (Fig. 2 F). To determine whether 
HO-1 is also required for IRF7 activation, a transcription   
factor that also regulates IFN- production, we stimulated 
control and HO-1–deficient macrophages with polyI:C and 
analyzed IRF7 mRNA induction. We found that IRF7 induc-
tion was similar in control and HO-1–deficient macrophages 
the cytoplasm and the nucleus with a dominance of export 
versus import, and a dimeric form that results from its phos-
phorylation at the C terminus and is sequestered in the nucleus 
(29). To investigate whether HO-1 is involved in the phos-
phorylation of IRF3, we treated TEPMs from control and 
HO-1M-KO mice with polyI:C, and phosphorylation of IRF3 
was detected by Western blotting using an antibody that   
specifically detects the phosphorylated form of IRF3. We 
found that activation of IRF3 was reduced in HO-1–deficient 
macrophages compared with controls (Fig. 2 E). In addition, 
IRF3 nuclear accumulation was detected by immunofluores-
ence. Consistent with the Western blotting and DNA-binding 
experiments, IRF3 nuclear accumulation was significantly   
Figure 2.  Defective IRF3 signaling and IFN- production in HO-1–deficient macrophages. (A) ELISA of IFN- production from BMDMs prepared 
from control (n = 3) and HO-1KO (n = 3) mice; cells were left untreated or stimulated for 24 h with polyI:C or LPS. Data are means ± SD of three indepen-
dent experiments. (B) Chemokine mRNA was analyzed by Northern blotting in LPS-treated TEPMs from control (n = 3) or HO-1M-KO (n = 3) mice.  
(C) Nuclear extracts (5 µg) from polyI:C-treated control or HO-1M-KO TEPMs were submitted to EMSA using an NF-B–specific probe. (D) The same nuclear 
extracts were submitted to EMSA using the ISG15 ISRE. IRF3 associated with coactivators and IRF3 dimers are shown. To confirm binding specificity,  
200-fold (lane 13) excess of unlabeled (cold) ISREs or NF-B probes were present during the binding reaction. In C and D, c represents a 200-fold excess 
of the unlabeled (cold) ISRE probe present during the binding reaction to confirm binding specificity. (E) Control and HO-1–deficient TEPMs were  
stimulated with polyI:C for the indicated time points, and WCEs were blotted with antibodies to p-IRF3 and IRF3 as loading control. (F) Control and  
HO-1–deficient TEPMs were stimulated with heme and/or polyI:C, and cell lysates were immunoprecipitated with anti-IRF3 antibody or isotype control. 
The precipitates were resolved on SDS-PAGE and transferred onto a membrane. The blot was probed with anti–HO-1 antibody. (G) Kinase activity of TBK-1 
was measured on WCEs from control and HO-1–deficient TEPMs by immune complex kinase assay (KA) using GST-IRF3 as substrate. For immunoblotting  
(IB), the top part of the gel was probed with a TBK-1 antibody to confirm equal amounts of the immunoprecipitated kinase. All experiments were  
performed at least two times. Black lines indicate that intervening lanes have been spliced out.JEM VOL. 206, May 11, 2009 
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HO-1 is required for in vivo innate immune responses  
to TLR3
Recent studies have shown that L. monocytogenes can induce 
IFN- once inside the cytoplasm of infected macrophages 
through the TBK-1–IRF3 signaling pathway (30, 31). IRF3-
mediated induction of type I IFNs results in enhanced sever-
ity of L. monocytogenes infection (30). Furthermore, it has 
been shown that intravenous injection of polyI:C results in 
strong induction of type I IFNs that enhance pathogenicity 
in response to polyI:C stimulation (Fig. S2). In addition, to 
determine whether lack of HO-1 affects the kinase activity of 
TBK-1, we performed a TBK-1 assay using cytoplasmic extracts 
from control and HO-1–deficient macrophages treated with 
polyI:C. We found that TBK-1 activity was similar in extracts 
derived from control and HO-1–deficient macrophages (Fig. 2 
G). Collectively, these results show that HO-1 specifically inter-
acts with IRF3 and affects its phosphorylation and subsequent 
nuclear translocation without affecting TBK-1 activity.
Figure 3.  HO-1 in macrophages is required for the generation of immune responses to bacterial and viral infections. (A) Control and HO-1M-KO 
mice were infected intravenously with 105 CFU L. monocytogenes or with a combination of 105 CFU L. monocytogenes and 200 µg polyI:C, and viability 
was assayed daily for 14 d. Data are representative of two independent experiments (means ± SEM of nine mice per group). (B) Liver sections from control 
and HO-1M-KO mice infected intravenously with 105 CFU L. monocytogenes either in the absence (a and b) or presence (c and d) of 100 µg polyI:C were 
stained with H&E to assess inflammation. Representative sections from two independent experiments with five mice per group are shown. Bars, 100 µM. 
(C) TEPMs from control (n = 3) and HO-1M-KO (n = 3) mice were infected with L. monocytogenes at different MOIs (circles) or L. monocytogenes and polyI:C 
(triangles) as indicated, and cell survival was measured by crystal violet staining after 24 h. Data are representative of two independent experiments 
(means ± SEM of three mice per group). (D) IFN- production was measured in supernatants from cultures in C (means ± SEM of three mice per group). 
(E) Control and HO-1M-KO mice were infected with 105 CFU L. monocytogenes or with a combination of 105 CFU L. monocytogenes and 200 µg polyI:C, and 
IFN- was measured in sera collected 24 h later. Data are representative of two independent experiments (means ± SEM of six mice per group). (F) TEPMs 
from control (n = 3) and HO-1M-KO (n = 3) mice were infected with SeV, and IFN- production was measured in supernatants after 24 h. Data are means ± 
SD of two independent experiments. (G) TEPMs from control (n = 3) and HO-1M-KO (n = 3) mice were infected with SeV for the indicated time points, and  
WCEs were probed for p-IRF3 and IRF3 as a loading control. Representative data from two independent experiments are shown. n.d., none detected.1172 HO-1 MODULATES IRF-3–DEPENDENT TYPE I INTERFERON PRODUCTION | Tzima et al.
Figure 4.  Macrophage-restricted ablation of HO-1 augments EAE. (A) Mean score of HO-1M-KO (n = 9) and littermate control (n = 9) mice at each 
measured time point. Results are representative of three different experiments (means ± SEM of nine mice per group). (B) Spinal cord sections from 
control (left) and HO-1M-KO (right) mice were stained with H&E to assess inflammation (top) and with LFB (bottom) to assess demyelination. Represen-
tative sections from two independent experiments with four mice per group are shown. Bars, 100 µM. (C) Immune cell infiltration into the CNS of con-
trol (n = 3) and HO-1M-KO (n = 3) mice. Infiltrates were stained with antibodies to CD45, CD11b, CD4, CD8, B220, and Gr-1 (R1 and R2 indicate gated 
areas). Numbers in quadrants indicate the percentages of cells in each. Data are representative of three independent experiments. (D) Co-stimulatory 
and MHC molecule expression in the CNS of HO-1M-KO mice. Immune cell infiltrates of control (shaded histograms; n = 4) and HO-1M-KO (open histograms; JEM VOL. 206, May 11, 2009 
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n = 4) mice were stained with antibodies to CD40, CD80, CD86, H-2Kb, and I-Ab. (E) Spinal cord cells from control (n = 3) and HO-1M-KO (n = 3) mice 
were harvested 25 d after infection, and the percentage of live CD4+ T cells that express intracellular IFN- and IL-17 with or without stimulation 
(PMA/ionomycin) was measured by flow cytometry analysis. The numbers in each quadrant represent the frequency of CD4+ T cells expressing IFN- 
and/or IL-17. Quantification and absolute numbers of IFN- and IL-17–producing T cells in the spinal cords of control and HO-1M-KO mice are also 
shown. Data are representative of three independent experiments.
 
during L. monocytogenes infection (30, 32). We have shown 
(Fig.  2)  that  HO-1–deficient  macrophages  have  defective 
IRF3 signaling and IFN- production, and we sought to de-
termine whether HO-1 deficiency can protect mice from 
IFN-–mediated sensitization to death during L. monocytogenes 
infection. We initially challenged control and HO-1M-KO 
mice with a sublethal dose of L. monocytogenes, and all mice 
remained healthy and viable (Fig. 3 A). Likewise, administra-
tion of polyI:C alone did not appear to influence the health 
status of the mice by day 14 (unpublished data). However, 
when mice were given a combination of a sublethal dose of 
L. monocytogenes along with polyI:C, only 10% of control 
mice remained viable, whereas 70% of HO-1M-KO mice 
survived the infection (Fig. 3 A). When a lower dose of   
polyI:C was used, only 40% of control mice remained viable, 
whereas all HO-1M-KO mice survived the infection (unpub-
lished data). Histological analysis of control livers from polyI:C- 
and L. monocytogenes–coadministered mice revealed multiple 
parenchymal abscesses as compared with livers from con-
trol mice that were infected with L. monocytogenes alone 
(Fig. 3 B, a and c). Consistent with the survival studies, livers 
from HO-1M-KO mice with or without coadministration of 
polyI:C were relatively clear of tissue abscesses (Fig. 3 B, 
b and d). Infection-borne IFN- plays an important role in 
sensitizing  macrophages  to  L.  monocytogenes–mediated  cell 
death (31), and mice deficient in IRF3 or IFNAR1 are more 
resistant to L. monocytogenes infection because their spleno-
cytes do not succumb to type I IFN–mediated apoptosis (30). 
To determine whether increased survival of HO-1M-KO mice 
is caused by reduced macrophage apoptosis, we infected con-
trol and HO-1–deficient macrophages with L. monocytogenes 
at different multiplicities of infection (MOIs) in the presence 
of polyI:C and measured cell death 24 h later. We found that 
80% of HO-1–deficient cells survived the infection com-
pared with 30% of control macrophages (Fig. 3 C). We also 
measured IFN- production in culture supernatants from 
control and HO-1–deficient macrophages infected with   
L. monocytogenes in the presence of polyI:C. HO-1–deficient 
macrophages  showed  significantly  attenuated  IFN-  pro-
duction as compared with control cells (Fig. 3 D), and this 
correlated with susceptibility to cell death. Finally, we mea-
sured  IFN-  production  in  serum  samples  from  control   
and HO-1M-KO mice challenged with a combination of a 
sublethal dose of L. monocytogenes along with polyI:C. In 
agreement with these in vitro data, IFN- production was 
severely impaired in HO-1M-KO mice as compared with con-
trols (Fig. 3 E). Collectively, these data suggest a major con-
tribution  of  HO-1  to  TLR3/IFN-–mediated  cell  death 
during L. monocytogenes infections.
HO-1 is required for IFN- production in response  
to virus infection
To gain insights into the biological relevance of macrophage 
HO-1  in  virus  infection–mediated  responses,  we  infected 
macrophages from control and HO-1M-KO mice with SeV. 
Detection of paramyxoviruses, including SeV, has been   
attributed mainly to the RNA helicase RIG-I and, to a lesser 
extent, the RIG-I–like receptor MDA5 (8). We found that pro-
duction of IFN- was severely impaired in HO-1–deficient 
macrophages infected with SeV as compared with control 
cells (Fig. 3 F). In addition, HO-1–deficient macrophages   
displayed severely impaired phosphorylation of IRF3 in   
response to SeV infection as compared with control macro-
phages (Fig. 3 G). Collectively, these results indicate that 
HO-1 is indispensable for triggering antiviral responses against 
SeV infection.
Myeloid-specific ablation of HO-1 exacerbates EAE and is 
not suppressed by polyI:C-mediated IFN- production
Multiple sclerosis is one of the diseases treated with IFN- 
(33, 34), and recent studies show that IFN- knockout mice 
have exacerbated EAE (35). More recent reports have also 
suggested a role for HO-1 in EAE, although the HO-1–me-
diated protective effects and their cellular basis remain largely 
unknown (20). When immunized with the encephalitogenic 
myelin  oligodendrocyte  glycoprotein  (MOG35-55)  peptide, 
HO-1M-KO  mice  developed  significantly  more  severe  and 
chronic  EAE  with  higher  incidence  compared  with  their 
control littermates (Fig. 4 A). Myeloid HO-1 deficiency did 
not affect the timing of disease onset but predominantly af-
fected the severity and chronicity of EAE. Moreover, no dif-
ferences in EAE severity between immunized LysMCre/+ mice 
and WT littermates were observed (Fig. S5), suggesting that 
expression of the Cre transgene in the LysM locus does not 
affect the course of EAE. To examine whether differences in 
EAE susceptibility and severity between HO-1M-KO and con-
trol mice lies in the priming of encephalitogenic T cells, we 
examined antigen-specific T cell responses in popliteal lymph 
nodes 8–10 d after infection. No differences were observed 
between HO-1M-KO and control mice regarding the capacity 
of T cells to proliferate (Fig. S6 A) or to produce IFN- and 
IL-4 (not depicted) in response to recall antigen. We next 
asked whether disease progression in HO-1M-KO mice may be 
caused by sustained autoreactivity of antigen-specific T cells. 
To address this, we examined the activation and differentia-
tion of myelin-specific T cells in immunized HO-1M-KO mice 
during the late relapse and remission stages. Splenocytes from 
HO-1M-KO mice showed a fourfold higher proliferation com-
pared with control cells and produced much higher levels of 1174 HO-1 MODULATES IRF-3–DEPENDENT TYPE I INTERFERON PRODUCTION | Tzima et al.
a preferential activation of the MyD88-independent, type I 
IFN–inducing TLR pathway has immunomodulatory poten-
tial in EAE and that disease suppression is associated with in-
creased levels of IFN- (36). Touil et al. performed in vivo 
neutralization experiments and showed that EAE protection 
by polyI:C was reversed by an anti–IFN- antibody, indi-
cating a role for IFN- in mediating this effect of polyI:C. 
To test whether exacerbation of EAE in HO-1M-KO mice was 
associated with defective IFN- production from macro-
phages, immunized HO-1M-KO and control mice were ad-
ministered polyI:C (30 µg/mouse/day) or PBS during the 
induction phase of EAE (days 5 and 8 after infection). Clinical 
signs of disease were suppressed in control mice that received 
polyI:C as compared with PBS-treated control mice. On the 
contrary, polyI:C-treated HO-1M-KO mice developed severe 
and chronic EAE that was similar to PBS-treated HO-1M-KO 
IFN- and TNF (Fig. S6, B–D) in response to MOG. Histo-
logical analysis of spinal cords of HO-1M-KO and control mice 
25 d after infection showed that HO-1M-KO mice had signifi-
cantly more cellular infiltration and demyelination through-
out the spinal cord compared with control mice (Fig. 4 B). 
Flow cytometry analysis of the immune cell infiltrates showed 
that HO-1M-KO mice had increased numbers of inflammatory 
cells, including CD4+ and CD8+ T cells, macrophages, and 
granulocytes, than did control mice (Fig. 4 C and Table S1). 
Infiltrating  macrophages  (CD45high  CD11b+Gr1)  showed 
increased expression of CD40, CD80, CD86, H-2Kb, and   
I-Ab (Fig. 4 D) as compared with controls. In the CNS of 
HO-1M-KO mice, we observed a fivefold increase in the num-
bers of IL-17–producing CD4+ T cells and a twofold increase 
in the numbers of IFN-–producing CD4+ T cells (Fig. 4 E) 
with an IL-17/IFN- ratio of >2:1. Recent studies show that 
Figure 5.  Clinical and histological effects of polyI:C administration in HO-1M-KO mice with EAE. (A) Control (n = 9) and HO-1M-KO (n = 10) mice 
were treated with intraperitoneal injections of polyI:C or PBS on days 5 and 8 after infection. Data are representative of three independent experiments 
(means ± SEM of at least nine mice per group). (B) Spinal cord sections from immunized, polyI:C-treated HO-1M-KO (a and c) and control (b and d) mice 
28 d after infection were stained with H&E and LFB. Representative sections from two independent experiments with five mice per group are shown. 
Bars, 100 µM. (C) Immunized HO-1M-KO mice were treated with intraperitoneal injections of polyI:C on days 5 and 8 after infection, and were either 
treated with PBS or with rhIFN- starting from day 9 after infection and continuing over a period of 14 d. Data are representative of two independent 
experiments (means ± SEM of 10 mice per group).JEM VOL. 206, May 11, 2009 
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bacterial  LPS  produce  several  proinflammatory  cytokines,   
including TNF (39), as well as antiinflammatory cytokines 
such as IL-10 (40). If macrophages overexpress HO-1 or are 
exposed to CO in vitro before stimulation with LPS, the 
proinflammatory response is markedly inhibited, whereas the 
antiinflammatory response is enhanced (16, 41). In addition, 
Lee and Chau identified a potential interplay between IL-10 
and HO-1 in the inhibition of LPS-induced inflammatory 
responses and provided evidence that HO-1 mediates the   
antiinflammatory function of IL-10 both in vivo and in vitro, 
and that IL-10 and HO-1 activate a positive feedback circuit 
to amplify the antiinflammatory response (17).
In this work, we have provided genetic evidence that 
identifies a novel function for myeloid HO-1 as an upstream 
mediator of the IRF3/IFN- response, orchestrating many 
subsequent processes central to innate as well as adaptive   
immune responses. Our data indicate that HO-1 forms a 
complex with IRF3 and is essential for IRF3 activation and 
subsequent  gene  expression  in  response  to  TLR3/TLR4 
stimulation. Although HO-1 can bind to its isoenzyme HO-
2 (42), no reports demonstrate binding of HO-1 to known 
transcriptions factors. A recent study by Lin et al. has shown 
that HO-1 is detected in the nucleus of cultured cells after 
exposure to hypoxia, and that HO-1 protein altered binding 
of transcription factors involved in oxidative stress (43). HO-1 
is not a traditional transcription factor with DNA binding 
motifs (44); therefore, direct transcriptional activation is less 
likely to occur. However, HO-1 could bind to other proteins, 
mice (Fig. 5, A and B). We then asked whether treatment 
with rIFN- can inhibit the clinical symptoms of EAE in 
myeloid HO-1–deficient mice. For this, immunized HO-
1M-KO mice were administered polyI:C and were treated with 
PBS or rIFN- (200,000 IU/day) starting from day 9 after 
infection and continuing over a period of 14 d. Clinical signs 
of disease were significantly suppressed in HO-1M-KO mice 
that received polyI:C and rIFN- as compared with HO-1M-KO 
mice that received polyI:C alone (Fig. 5 C). Collectively, 
these data show that absence of myeloid HO-1 exacerbates EAE 
characterized by enhanced infiltration of macrophages and 
Th17 cells, and a nonregressing myelin-specific T cell reac-
tivity. Furthermore, we showed that regulation of autoim-
mune disease in HO-1M-KO mice critically depends on IFN- 
production, demonstrating an essential requirement for HO-1 
in this pathway.
DISCUSSION
HO-1 is known to be involved in a vast array of pathophysio-
logical conditions (37, 38). HO-1 expression or CO adminis-
tration mediate potent antiinflammatory effects in monocytes 
and/or macrophages, probably restraining these cells from   
inducing tissue injury and modulating their role in the initia-
tion of immune responses. Several studies have shown the 
protective effects of the HO-1/CO system; CO suppresses the 
proinflammatory and promotes the antiinflammatory response 
of macrophages, a cell type that controls the balance of inflam-
mation in many conditions. Macrophages stimulated with 
Figure 6.  A proposed model implicating myeloid HO-1–mediated regulation of immune cytokines and responses. Upon TLR4 stimulation,  
HO-1 is not required for the early phase MyD88- or TRIF-dependent activation of MAPKs and NF-B but is required for the suppression of inflammatory 
responses at later time points. On the other hand, early phase activation of the TRIF–IRF3 and RIG-I–IRF3 pathways requires HO-1 for the production of  
antiviral cytokines, TLR3/4 primary response genes, and the development of adaptive immune responses.1176 HO-1 MODULATES IRF-3–DEPENDENT TYPE I INTERFERON PRODUCTION | Tzima et al.
activation of the TLR3–type I IFN–inducing pathway by 
polyI:C suppresses EAE through induction of endogenous 
IFN-. IFN- is used for the treatment of multiple sclerosis; 
its mechanisms of action include induction of IL-10, inhibition 
of the expansion of encephalitogenic T cells (45), reduced 
production of inflammatory cytokines, and reduction of blood–
brain barrier permeability (46, 47). In the absence of myeloid 
HO-1, activation of the type I IFN–inducing pathway by polyI:
C treatment did not suppress the development of disease in 
immunized HO-1M-KO mice. In contrast, rIFN-–treated 
HO-1M-KO mice displayed low clinical scores, suggesting that 
the protective effects of HO-1 are mediated through endog-
enous IFN- induction.
In conclusion, our findings demonstrate a multilayered 
functioning of HO-1 in immunity and disease, with an early 
critical involvement of this molecule in IRF3-driven innate 
immune activation and with subsequent enzymatic activities 
that are known to confer cell and tissue protective antiinflam-
matory, antiapoptotic, antiproliferative, and antioxidant effects 
(37). Differential modulation of such enzymatic and/or signal-
ing activities of HO-1 may hold clues for more effective thera-
peutic uses of this molecule in a range of immune pathologies.
MATERIALS AND METHODS
Generation of Hmox1 conditional knockout mice. Phage clones con-
taining mouse Hmox1 were isolated by screening of a 129/Svev genomic   
library (UK Human Genome Mapping Project Resource Centre) with a probe 
corresponding to the 5 end of mouse HO-1 cDNA. A targeting vector was 
designed to flank exons 3 and 4, with two loxP sites. The floxed neomycin-
resistance gene fragment was inserted into intron 2 of Hmox1. A 5.2-kb NotI-
NotI fragment (exons 1 and 2) was used as the 5 homology region; a 2.1-kb 
XhoI-SpeI fragment, which contains exons 3 and 4 of Hmox1, was inserted 
between the two loxP sites; and a 2.1-kb NheI-BamHI fragment was used as 
the 3 homology region. The herpes simplex virus thymidine kinase gene was 
used for negative selection of clones with random integration. A total of 20 
µg of linearized vector was electroporated into 129/3 embryonic stem cells 
(provided by N. Brockdorff, University of Oxford, Oxford, England, UK). 
After positive and negative selection with G418 and gancyclovir, drug-resistant 
clones were picked up and screened by PCR and Southern blot analysis. 
These clones were individually microinjected into blastocysts derived from 
C57BL/6 mice and were transferred to pseudopregnant females. Matings of 
chimeric male mice to C57BL/6 female mice resulted in transmission of the 
floxed allele to the germline. Chimeric mice were bred to CMV-Cre transgenic 
mice (21) to remove the neomycin cassette. All mice were housed under   
specific pathogen-free conditions, and animal protocols used in this study 
were approved by the Institutional Animal Care and Use Committee of the 
Biomedical Sciences Research Center “Alexander Fleming.”
Cell cultures and reagents. TEPMs and BMDMs were grown as previously 
described (1, 48). For the IFN- (PBL Biomedical Laboratories), IL-6 (Thermo 
Fisher Scientific), and TNF (provided by W. Buurman, Nutrition and Toxi-
cology Research Institute Maastricht, Maastricht, Netherlands) ELISA assays, 
macrophage cultures (5 × 105 cells/well) were incubated with 1 µg/ml LPS 
(Salmonella enteriditis; Sigma-Aldrich) or 100 µg/ml polyI:C (GE Healthcare).
Viral infections. SeV Cantell strain was provided by D. Thanos (Academy 
of Athens, Athens, Greece) and was used to infect macrophages (106 cells/ml) 
at 100 hemagglutination U/ml for the time points indicated in the figures.
Bacterial infections and assays to measure cell death. Preparation of 
L. monocytogenes and in vivo infections were previously described (30). Mac-
rophages (106 cells/well) were infected with L. monocytogenes (derived from 
serving as the non-DNA binding protein of a transcriptional 
factor complex, or could be a scaffold protein, acting as a 
chaperone  for  unstable  client  proteins  and  keeping  them 
poised for activation. It remains to be determined how HO-1 
modulates transcription factor activity and if modulation of 
these factors is mediated by HO-1 protein or its byproducts, 
such as CO. Recent reports have also suggested a role for CO 
in the regulation of TLR signaling pathways. CO treatment 
was shown to negatively control TLR signaling by inhibit-
ing translocation of TLRs to lipid rafts (10). In the same 
study, although CO inhibited TLR4 signaling and subse-
quent IFN- production after LPS stimulation, it did not af-
fect TLR3-dependent signaling in macrophages in response 
to polyI:C treatment. Therefore, it appears that the observed 
effects of CO on the TLR3 signaling pathway are indepen-
dent of the HO-1 protein function. This is supported by the 
observation of Hegazi et al. (11) that CO inhibits the syner-
gistic activation of IL-12 p40 and inducible nitric oxide syn-
thase by LPS/IFN- through selective inhibition of IRF8. 
The immunological effects of CO required HO-1, and in the 
absence of functional HO-1, the inhibitory action of CO on 
IRF8 and IL-12 p40 expression was lost. In agreement with 
this, we have not observed a defect in IRF8 activation in   
macrophages from HO-1M-KO mice in response to LPS/IFN- 
(unpublished data). These results suggest that the products   
of the HO-1 pathway impart antiinflammatory effects via   
different modes of action and that HO-1 may have a cyto-
protective role independent of its two major metabolic by-
products. Collectively, these findings reveal a multifaceted 
role for HO-1 in immune responses, presented schematically 
in Fig. 6; in response to bacterial or viral stimuli, HO-1 is   
required  for  early  activation  of  the  type  I  IFN–inducing 
pathway and subsequent development of antiviral or adaptive 
immunity. At a later time point, HO-1, through CO produc-
tion, acts to inhibit the proinflammatory response and en-
hance the antiinflammatory effects of IL-10.
The  physiological  significance  of  the  HO-1–mediated 
type I IFN induction was shown using a bacterial/viral in-
fection model in which polyI:C dramatically sensitizes mice 
to L. monocytogenes inoculation in an IFNAR1-dependent 
manner (30). Even though the complete mechanism by which 
type I IFNs inhibit host immunity to L. monocytogenes is 
likely complex because of the pleiotropic cellular effects me-
diated by these cytokines, there is evidence showing that 
IRF3-dependent production of IFN- by the infected mac-
rophages induces apoptosis in neighboring cells and, possi-
bly, macrophages themselves (30, 31). In accordance, mice 
with  myeloid-specific  HO-1  deficiency  were  resistant  to 
polyI:C/L. monocytogenes infection, and this was associated 
with reduced IFN- production in vivo. In addition, we 
showed that HO-1 deficiency exacerbated an autoimmune 
condition that is dependant on endogenous IFN- produc-
tion. Absence of myeloid HO-1 exacerbated EAE in mice, 
and this was associated with enhanced leukocyte accumula-
tion within the CNS, including Th17 cells and nonregressing 
myelin-specific T cell responses. It was recently shown that JEM VOL. 206, May 11, 2009 
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TCTGGTGTCA-3),  PKRf  (5-TTGGCTTAGGTGGATTTGGT-3), 
PKRr  (5-TTCTGTTTCTCATCCATTGC-3),  B2Mf  (5-TTCTGGT-
GCTTGTCTCACTGA-3), and B2Mr (5-CAGTATGTTCGGCTTC-
CCATTC-3).
Induction of EAE and rIFN- treatment. Induction of EAE was per-
formed as previously described (48) with 50 µg of rat MOG peptide in 
CFA containing a total of 1 mg H37Ra per mouse. rhIFN- (Betaferon; 
Schering-Plough) was administered for 14 d using mini-osmotic pumps 
(model 2002; Alzet).
Spinal cord flow cytometry. Spinal cord cells were isolated as previ-
ously described (50). For flow cytometry, cells were stained for 30 min at 
4°C with various primary antibodies (BD). Cells were analyzed with a flow 
cytometer (FACSCalibur; BD).
Histological  analysis. Mice were perfused with PBS and spinal cords 
were fixed in 10% buffered formalin. The spinal cords were dissected and 
paraffin embedded before staining with hematoxylin and eosin (H&E) to 
assess inflammation, and luxol fast blue (LFB) to assess demyelination.
Online supplemental material. Fig. S1 shows activation of the MAPK 
and NF-B signaling cascades and proinflammatory cytokine production in 
HO-1–deficient macrophages. Fig. S2 depicts the induction of genes encod-
ing LPS/dsRNA receptors in HO-1–deficient macrophages. Fig. S3 shows 
that HO-1 is not induced by IFN- or dsRNA and is induced by LPS. Fig. 
S4 shows that nuclear translocation of IRF3 is impaired in HO-1–deficient 
macrophages. Fig. S5 depicts the development of EAE in LysMCre/+ knockin 
and WT mice. Fig. S6 depicts the proliferation and cytokine production of 
LNs and spleen cells from HO-1M-KO and control mice immunized with 
MOG35-55. Table S1 shows the quantification of CNS-infiltrating cells dur-
ing the chronic phase of EAE. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20081582/DC1.
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